Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
active_not_recruiting120%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
active_not_recruitingphase_3

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT07196774
recruitingphase_2

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

NCT06504732
recruitingphase_2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05800275
completedphase_3

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

NCT01875367
completedphase_1

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

NCT04175171

Clinical Trials (5)

Showing 5 of 5 trials
NCT07196774Phase 3

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Active Not Recruiting
NCT06504732Phase 2

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Recruiting
NCT05800275Phase 2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Recruiting
NCT01875367Phase 3

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Completed
NCT04175171Phase 1

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5